Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brodalumab for Moderate Hidradenitis Suppurativa
NCT03910803Phase 2Unknown
- Sponsor
- Florida Academic Dermatology Centers
- Start
- May 2019
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brodalumab in hidradenitis suppurativa (HS), sponsored by Florida Academic Dermatology Centers. Primary endpoint: Hidradenitis Suppurativa Clinical Response at 16 weeks. Status: unknown.
02
Drugs
brodalumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT03910803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03910803.